Influenza due to other identified influenza virus with unspecified type of pneumonia
Methodology & AI Transparency ⓘ
Influenza due to other identified influenza virus with unspecified type of pneumonia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code J10.00 in Infections & Antivirals, Influenza due to other identified influenza virus with unspecified type of pneumonia requires antimicrobial stewardship (narrow-spectrum in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: pathogen-directed duration) or) so specialists can calibrate treatment intensity against C-Reactive Protein / in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: Procalcitonin) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Influenza due to other identified influenza virus with unspecified type of pneumonia uses ICD-10 J10.00 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Differential triage of Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00) utilizes antimicrobial stewardship (narrow-spectrum in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Objective lab/clinical target for Influenza due to other identified influenza virus with unspecified type of pneumonia: C-Reactive Protein / in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: Procalcitonin) (Resolution to baseline (J10.00)) and Targeted PCR / in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: Culture & Sensitivity).
Ask our AI Specialists anything about Influenza due to other identified influenza virus with unspecified type of pneumonia
What Is Influenza due to other identified influenza virus with unspecified type of pneumonia?
Cataloged under federal diagnostic code J10.00 in Infections & Antivirals, Influenza due to other identified influenza virus with unspecified type of pneumonia requires antimicrobial stewardship (narrow-spectrum in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: pathogen-directed duration) or) so specialists can calibrate treatment intensity against C-Reactive Protein / in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: Procalcitonin) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Influenza due to other identified influenza virus with unspecified type of pneumonia (ICD-10 J10.00) is driven by or latent viral in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: reactivation within sensory); specialists in Bacterial, Viral & Fungal Infections monitor Targeted PCR / in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: Culture & Sensitivity) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00): regional lymph node in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: tenderness or acute)
- • Secondary Influenza due to other identified influenza virus with unspecified type of pneumonia clinical sign: acute fever, chills, in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: malaise, and myalgias)
- • Symptom flares in Influenza due to other identified influenza virus with unspecified type of pneumonia correlating with C-Reactive Protein / in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: Procalcitonin) deviation outside Resolution to baseline (J10.00)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: pathogen-directed duration) or) evaluation (J10.00)
Influenza due to other identified influenza virus with unspecified type of pneumonia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J10.00 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: C-Reactive Protein / in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: Procalcitonin) | Resolution to baseline (J10.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: Culture & Sensitivity) | Pathogen clearance / negative test (J10.00) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Influenza due to other identified influenza virus with unspecified type of pneumonia (J10.00: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (J10.00) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Influenza due to other identified influenza virus with unspecified type of pneumonia
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Gocovri (Amantadine) Gocovri • RxCUI 849389-B70482085 | Influenza A M2 Protein Inhibitor | 81% | $0.1559 | $ 19.72 /mo |
| Oseltamivir Phosphate Tamiflu • RxCUI 1115698 | Neuraminidase Inhibitor | 77% | $0.6443 | $ 14.76 /mo |
| Amantadine HCl (Amantadine Hydrochloride) Amantadine HCl • RxCUI 849389-B42291125 | Influenza A M2 Protein Inhibitor | 87% | $0.1410 | $ 18.65 /mo |
| Zanamivir Relenza • RxCUI 759471 | Neuraminidase Inhibitor | 94% | $2.8319 | $ 123.19 /mo |
| Amantadine HCl Symmetrel • RxCUI 849389 | Influenza A M2 Protein Inhibitor | 86% | $0.1559 | $ 6.48 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Influenza due to other identified influenza virus with unspecified type of pneumonia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine: What a 2,100-Participant Study Found IIV4-HD provided superior immunogenicity versus IIV4-SD and was well tolerated in participants ≥ 60 years of age in Japan. Vaccine • 2023-04-06 • Phase III Randomized Trial | N = 2,100 | 96/100 | PMID 36906404 ↗ |
| Can You Get Your RSV and Flu Shots at the Same Visit? What a 1,900-Adult Trial Found Coadminstration is estimated to maintain the efficacy of mRNA-1345 against RSV-lower breathing tract disease based on a correlate of protection model. Human vaccines & immunotherapeutics • 2026-12-15 • Phase III Randomized Trial | N = 1,900 | 96/100 | PMID 42048601 ↗ |
| New Insights on Immunogenicity and safety of live attenuated influenza vaccine in children aged: What a 3,000-Participant Study Found (3) Results: Although there was no significant difference in frequencies of all solicited or unsolicited AEs, nasal congestion, headache, and muscle pain were statistically significantly more frequent in vaccine recipients as... Vaccine • 2025-02-06 • Phase III Randomized Trial | N = 3,000 | 96/100 | PMID 39729925 ↗ |
| New Insights on High-Dose Quadrivalent Influenza Vaccine for Prevention of heart and blood vessel: What a 16,549-Participant Study Found Despite insufficient statistical power due to the impact of COVID-19, rVE point estimates demonstrated a trend toward a benefit of QIV-HD over QIV-SD. Influenza and other respiratory viruses • 2024-04-15 • Phase III Randomized Trial | N = 16,549 | 96/100 | PMID 38569647 ↗ |
| New Insights on Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal: What a 1,200-Participant Study Found Consistent with previous studies, a trend was observed toward lower pneumococcal OPA GMTs in the concomitant versus the non-concomitant group. Human vaccines & immunotherapeutics • 2022-12-31 • Phase III Randomized Trial | N = 1,200 | 96/100 | PMID 34726574 ↗ |
Influenza due to other identified influenza virus with unspecified type of pneumonia Patient Community & “People Like Me” Threads
Filter Influenza due to other identified influenza virus with unspecified type of pneumonia community threads and patient logs by age, biological sex, dosage, and treatment duration.